This article was originally published in The Gray Sheet
CaverMap surgical aid for use in sparing vital nerves during prostate surgery will be launched at the American Urological Association meeting in San Diego May 30-June 4. The Needham, Massachusetts firm begins a six-center clinical study involving over 100 patients designed to "quantify the benefits to patients and surgeons utilizing" the device, which received FDA clearance in October ("The Gray Sheet" Nov. 3, 1997, I&W-11)...
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.